Stereotaxis to Report First Quarter Financial Results on May 10, 2022
Stereotaxis (NYSE: STXS) announced it will release its 2022 first quarter financial results on May 10, 2022, before U.S. markets open. The company will host a conference call at 10 a.m. EST to discuss the results and corporate developments. Investors can access the call at 888-254-3590 (US) or 1 929-477-0448 (International) using passcode 5168103. A replay will be available for one month after the call. Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, having treated over 100,000 patients globally.
- Stereotaxis will provide a financial update on May 10, 2022, allowing investors insight into performance.
- The company is recognized as a pioneer in surgical robotics, enhancing patient care and procedure efficiency.
- None.
ST. LOUIS, April 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 first quarter on Tuesday, May 10, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.
What: | Stereotaxis first quarter 2022 financial results conference call | |
When: | Tuesday, May 10, 2022 at 10:00 a.m. EST (7:00 a.m. PST) | |
Dial In Number: | To access the live call, dial 888-254-3590 (US and Canada) or 1 929-477-0448 (International) and give the participant pass code 5168103. | |
Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. | |
Call Replay: | A phone replay of the call will be available for one month beginning approximately two hours following the end of the call. To request access for a replay of the conference call, please click here. | |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
FAQ
When will Stereotaxis release its Q1 2022 financial results?
What time is the Stereotaxis conference call for Q1 2022 results?
How can I access the Stereotaxis Q1 2022 conference call?